Ketorolac

證據等級: L5

預測適應症: 3 個

Ketorolac: From Acute Pain Management to Headache Disorder

One-Sentence Summary

Ketorolac is a well-established non-steroidal anti-inflammatory drug (NSAID) widely used globally for acute pain management, including postoperative and musculoskeletal pain. The TxGNN model predicts it may be effective for Headache Disorder (including migraine and tension-type headache), with 36 clinical trials and 19 publications currently supporting this direction — many of which test ketorolac as the primary or reference intervention.

Quick Overview

Item	Content
Original Indication	Acute pain management (not currently registered in India)
Predicted New Indication	Headache Disorder (migraine, tension-type headache)
TxGNN Prediction Score	99.43%
Evidence Level	L1
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the evidence pack. Based on well-established pharmacological knowledge, Ketorolac is a potent NSAID belonging to the pyrrolizine carboxylic acid class. It exerts its analgesic and anti-inflammatory effects primarily through non-selective inhibition of cyclooxygenase enzymes (COX-1 and COX-2), which reduces the biosynthesis of prostaglandins, thromboxanes, and prostacyclins. This mechanism underlies its efficacy across a broad range of pain conditions.

The connection to headache disorder is mechanistically sound. Prostaglandins — particularly PGE2 — play a well-documented role in sensitising trigeminal pain pathways, promoting neurogenic inflammation, and triggering vasodilation, all of which contribute to migraine attacks and tension-type headaches. By suppressing prostaglandin synthesis at the site of inflammation, Ketorolac can interrupt these pain cascades without acting on opioid receptors, making it an attractive non-opioid analgesic option in emergency and clinical headache management.

The clinical evidence further validates this prediction. Multiple Phase 3 and Phase 4 randomised controlled trials have specifically tested Ketorolac as a first-line or comparator treatment for acute migraine and tension-type headache in emergency department settings — across both adult and paediatric populations. Systematic reviews by major headache societies (American Headache Society, Canadian Headache Society) have explicitly included Ketorolac in their evidence-based treatment algorithms, cementing its role as a clinically recognised intervention in headache disorders.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01267864	Phase 4	Completed	330	Three-arm RCT comparing IV valproate, IV metoclopramide, and IV ketorolac for acute migraine in the ED
NCT01011673	Phase 4	Completed	123	Ketorolac vs metoclopramide/diphenhydramine for acute tension-type headache in the ED
NCT05641363	Phase 3	Completed	171	Dose-comparison RCT of ketorolac in children with acute pain (including headache)
NCT02358681	Phase 3	Completed	59	Intranasal vs intravenous ketorolac for migraine in paediatric patients; non-inferiority design
NCT00483717	Phase 2	Completed	173	Double-blind, placebo-controlled trial of intranasal ketorolac for acute migraine treatment
NCT01807234	Phase 4	Completed	72	Ketorolac nasal spray vs sumatriptan nasal spray vs placebo for acute migraine abortive therapy
NCT01596166	Phase 4	Completed	56	Combination IV ketorolac + metoclopramide for paediatric migraine in the ED
NCT03221569	Phase 4	Unknown	60	Sub-dissociative ketamine vs ketorolac for acute tension-type headache in the ED
NCT02664116	Phase 4	Unknown	40	IM ketorolac vs oral diclofenac potassium powder for severe migraine
NCT06083571	Phase 2	Terminated	41	Intranasal ketorolac + oral adjuncts vs IV ketorolac for paediatric migraine; non-inferiority design

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35138658	2022	Systematic Review & Meta-analysis	Academic Emergency Medicine	Evaluated efficacy of parenteral ketorolac specifically for acute migraine; pooled analysis of RCTs
39674934	2025	Systematic Review & Bayesian Network Meta-analysis	Annals of Emergency Medicine	Compared pharmacological therapies for migraine in the ED; assessed relative efficacy and safety including ketorolac
41321235	2026	Clinical Guideline	Headache	2025 AHS guideline update on parenteral pharmacotherapies for acute migraine management in the ED
25600718	2015	Evidence Assessment (Review)	Headache	American Headache Society updated evidence assessment of acute migraine pharmacotherapies
24875925	2015	Systematic Review	Cephalalgia	Canadian Headache Society systematic review and recommendations for migraine pain treatment in emergency settings
35670115	2022	RCT	Headache	RCT comparing IV metoclopramide alone vs metoclopramide + ketorolac in paediatric ED migraine; assessed efficacy and safety
30783794	2019	RCT	Neurological Sciences	Prospective double-blind RCT comparing dexamethasone, metoclopramide, ketorolac, and chlorpromazine for migraine pain and recurrence
37849443	2024	Systematic Review & Meta-analysis	Advances in Clinical and Experimental Medicine	Updated meta-analysis comparing IV ketorolac vs metoclopramide in adult migraine; synthesised recent trial data
9484382	1998	RCT	Neurology	Three-arm controlled trial of IM ketorolac vs meperidine/promethazine vs placebo for acute tension-type headache
1514724	1992	RCT	Annals of Emergency Medicine	Early RCT comparing IM ketorolac vs meperidine/hydroxyzine for acute migraine headache in the ED

India Market Information

Ketorolac currently has no registered products in India. No licence data is available for display.

Safety Considerations

Drug Interactions (222 interactions identified; key interactions listed below):

Severity	Interacting Drug(s)	Clinical Note
Major	Acetylsalicylic acid (Aspirin)	Concurrent use significantly increases risk of gastrointestinal bleeding and renal toxicity; combination generally contraindicated
Moderate	Corticosteroids (Betamethasone, Budesonide, Dexamethasone, Hydrocortisone)	Combined NSAID + steroid use increases GI ulceration and bleeding risk
Moderate	Sulfonylureas (Glimepiride, Glipizide, Glyburide, Chlorpropamide, Acetohexamide)	NSAIDs may enhance hypoglycaemic effect; blood glucose monitoring advised
Moderate	Levofloxacin	May increase risk of CNS adverse effects and seizures
Moderate	Kanamycin	Potential for additive nephrotoxicity
Moderate	Exenatide, Fenfluramine, Dexfenfluramine	Metabolic and pharmacodynamic interactions warranting monitoring
Minor	Famotidine, Ranitidine, Cimetidine	H2 blockers may alter ketorolac absorption or gastric protection context; clinically minor

Note: Detailed warnings and contraindications from Indian regulatory labelling (package insert) are not currently available. Please refer to the internationally approved prescribing information (e.g., FDA or EMA label) for full safety guidance pending local data acquisition.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The evidence supporting Ketorolac for headache disorder is exceptionally strong — multiple completed Phase 3 and Phase 4 RCTs have directly tested its efficacy for acute migraine and tension-type headache, and it is explicitly endorsed in major international headache society guidelines (American and Canadian). The TxGNN prediction aligns with established clinical practice globally. However, Ketorolac is not currently marketed in India, and no local regulatory safety data (package insert, CDSCO approval status) has been retrieved, which creates a significant gap for market entry assessment.

To proceed, the following is needed:

Regulatory pathway in India: Initiate CDSCO registration process or investigate whether Ketorolac can be imported under existing frameworks
Local safety labelling: Obtain and review the full package insert from a reference agency (FDA/EMA) for warnings, contraindications, and special population data
Mechanism of action data: Query DrugBank API (DB00465) to formally document COX-1/COX-2 inhibition profile for the regulatory dossier
Indication specificity: Clarify the target indication (migraine vs tension-type vs post-dural puncture headache) to align with the most robust Phase 3 evidence for the regulatory submission
Formulation strategy: Determine preferred route of administration (IV, IM, or intranasal) given India’s clinical setting; intranasal formulation has Phase 3 non-inferiority data vs IV and may ease administration
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.